Raquel Nunes

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Yvette Latchman, Clive R. Wood, Tatyana Chernova et al. · Nature Immunology · 2001 · 2.9K citations

Life Sciences, Cell Biology, Immunology +14

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein, Lyndsay N. Harris, P. Kelly Marcom et al. · Journal of Clinical Oncology · 2003 · 345 citations

Medicine, Oncology, Pharmacology +17

Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study

Harold J. Burstein, Lyndsay N. Harris, Rebecca Gelman et al. · Journal of Clinical Oncology · 2002 · 277 citations

Medicine, Oncology, Pharmacology +17

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Filipa Lynce, Ana Barac, Xue Geng et al. · Breast Cancer Research and Treatment · 2019 · 145 citations · Full text

Medicine, Cardiology, Oncology +17

A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique

Stephan Mielke, Raquel Nunes, Katayoun Rezvani et al. · Blood · 2007 · 111 citations · Full text

Life Sciences, Hematology, Immunology +17